Resource Summary Report

Generated by kravitz2 on Sep 1, 2026

pLenti CMV GFP Hygro (656-4)

RRID:Addgene_17446
Type: Plasmid

Proper Citation

RRID:Addgene_17446

Plasmid Information

URL: http://www.addgene.org/17446

Proper Citation: RRID:Addgene_17446

Insert Name: GFP

Bacterial Resistance: Ampicillin

Defining Citation: PMID:19657394

Vector Backbone Description: Backbone Size:8591; Vector Backbone:p156RRL-sinPPT-CMV-GFP-PRE/Nhe I; Vector Types:Mammalian Expression, Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pLenti CMV GFP Hygro (656-4)

Record Creation Time: 20220422T222008+0000

Record Last Update: 20260829T080028+0000

Ratings and Alerts

No rating or validation information has been found for pLenti CMV GFP Hygro (656-4).

No alerts have been found for pLenti CMV GFP Hygro (656-4).

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. Cancer research, 86(6), 1414.

Becker AP, et al. (2026) Photosensitizer proximity labeling captures the lipid and protein interactomes. Nature chemical biology.

Lee JH, et al. (2026) N6-adenosine methylation enhances nuclear mRNA export through METTL3 and NUP93. Nature cell biology, 28(3), 553.

Li S, et al. (2026) Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model. Cell reports. Medicine, 7(6), 102830.

Boyack I, et al. (2025) A Potential Role for c-MYC in the Regulation of Meibocyte Cell Stress. Cells, 14(10).

Baldacci S, et al. (2025) Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy. Cancer discovery.

Obuchi W, et al. (2025) Engineering of CD63 Enables Selective Extracellular Vesicle Cargo Loading and Enhanced Payload Delivery. Journal of extracellular vesicles, 14(6), e70094.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell stem cell, 32(3), 463.

Niceforo A, et al. (2025) Analysis of astrocyte progenitors derived from human induced pluripotent stem cells in vitro and following transplantation into the intact spinal cord. bioRxiv : the preprint server for biology.

Hu X, et al. (2025) The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2. Immunity, 58(4), 946.

Wang X, et al. (2025) PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. Cancer discovery, 15(3), 633.

Chau LF, et al. (2025) Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease. Nature communications, 16(1), 766.

Brea EJ, et al. (2025) Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. Cancer immunology research, 13(11), 1749.

Hwang SP, et al. (2025) TRMT1L-catalyzed m22G27 on tyrosine tRNA is required for efficient mRNA translation and cell survival under oxidative stress. Cell reports, 44(1), 115167.

Youn D, et al. (2025) Cross-talks between Metabolic and Translational Controls during Beige Adipocyte Differentiation. Nature communications, 16(1), 3373.

Carstens EJ, et al. (2025) Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nature communications, 16(1), 9651.

Palma FR, et al. (2024) Histone H3.1 is a chromatin-embedded redox sensor triggered by tumor cells developing adaptive phenotypic plasticity and multidrug resistance. Cell reports, 43(3), 113897.

Acosta Montaño P, et al. (2024) Development of Liver-Targeting ?V?5+ Exosomes as Anti-TGF-? Nanocarriers for the Treatment of the Pre-Metastatic Niche. Biology, 13(12).

Klomp JE, et al. (2024) Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. Science (New York, N.Y.), 384(6700), eadk0850.

Ma J, et al. (2024) Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression. Scientific reports, 14(1), 14914.